Clinical and Immunohistochemical Evaluation of Medullary Thyroid Cancer (MTC) and C Cell Hyperplasia (CCH) Abstract #299

Introduction: MTC and CCH has a variable clinical presentation and prognosis and no data are available on the correlation between immunoistochemical (IIC) characterization and clinical behavior.
Aim(s): Evaluation of clinical behavior, prognosis and IIC expression (PTTG-1, SSTR2A, VEGFR-1, -2 and -3) in 23 patients affected by MTC and/or CCH.
Materials and methods: Twenty-three patients affected by MTC and/or CCH were included. All patients underwent total thyroidectomy, pre- and post-operative calcitonin assay, staging, histological examination, IIC evaluation of expression of PTTG-1, SSTR2A, VEGFR-1, -2 and -3.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Prof Laura De Marinis

To read results and conclusion, please login ...

Further abstracts you may be interested in

#142 The role of 18F DOPA-PET in a case of malignant pheochromcytoma
Introduction: Pheocromocytoma is a rare tumor arising from chromaffin cells of adrenal medullary or extra adrenal paraganglionic tissue. Histological criteria cannot differentiate benign from malignant pheocromocytomas. The diagnosis of a malignant pheocromocytoma requires local invasion, recurrence and documented metastatic disease. The radionuclide scanning (123I - 131I-MIBG) is a fundamental diagnostic tool used to confirm the biochemical and radiological diagnosis of pheochromocytoma. In fact, MIBG scanning may confirm that the visualised lesion in an adrenal gland is indeed a pheochromocytoma and detect extra-adrenal paraganglionic tissue. However, MIBG scans are negative in around 15% of benign pheochromocytomas and in up to 50% of malignant ones. Other radionuclide techniques (18FDG-PET, 18F-DOPA-PET, 18F-FDA-PET) have been successfully used in investigation of pheochromocytomas. 18F-DOPA-PET and 18F-FDA-PET have been reported to be highly sensitive and specific for benign pheochromocytomas, while 18FDG-PET can be useful for malignant lesions with higher metabolic activity.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Prof. Laura De Marinis
#34 Plasma Chromogranin A(CgA) and Urinary 5 Hydroxy-indoleacetic acid(5-HIAA) use in monitoring somatostatin analogue(SSA) therapy at Newcastle NHS Foundation Trust
Introduction: Two main biochemical markers, plasma chromogranin A (CgA) and urinary 5 hydroxy-indoleacetic acid (5-HIAA) are used to aid staging and monitoring of patients with neuroendocrine (NET) tumors. Somatostatin analogues (SSA) such as octreotide and lanreotide have been used to alleviate symptoms and disease progression in NET patients. This study evaluates the use of CgA and 5HIAA in monitoring NET patients on SSA therapy at Newcastle NHS Foundation Trust.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Andy James
Authors: Teo L, Hearn K, Bernstone G, Wright R, ...
#301 Medical and Peptide Receptor Radionuclide Therapy (PRRT) with Somatostatin Analogues (SSA) in Well- and Moderately Differentiated Neuroendocrine Tumors
Introduction: PRRT is a treatment choice for inoperable or metastasized neuroendocrine tumors and this therapy seems more effective in the biochemical and volume control of disease than SSA alone.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Prof Laura De Marinis
#1141 New Hybrid SPECT-CT Modality for Imaging Purposes in Patients with Medullary Thyroid Cancer (MTC)
Introduction: Loco-regional lymph node and distant metastases are found very often in patients with MTC of less than 1 cm. There is not good MTC response to systemic chemotherapy or to external been radiotherapy. Radical thyroidectomy is the main method of therapy. Early diagnosis and correct N/M-staging are extremely important for the management of MTC. New hybrid SPECT-CT γ-cameras allow the fusion of anatomical and functional modalities. SPECT-CT is used in order to optimize somatostatin-receptor scintigraphic protocols.
Conference: 12th Annual ENETS Conference (2015)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Professor Sonya Sergieva
#1907 Pancreatic Neuroendocrine Tumors in MEN1 Disease: A Monocentrice Longitudinal and Prognostic Study
Introduction: In MEN1+ patients (MEN+), pNETs are considered to be high risk for multiple, malignant and aggressive tumors.
Conference: 14th Annual ENETS conference (2017)
Category: Pathology, grading, staging
Presenting Author: md Sabrina Chiloiro
Keywords: pNETs, MEN, prognosis